Literature DB >> 31910408

Lupus Nephritis Class IV-Global Is Associated with a Higher Risk of End-Stage Renal Disease than Class IV-Segmental.

Camila Oliveira1, Henrique Mariz2, Gisele Fernandes3, Denise Costa3, Maria Alina Cavalcante3, Lucila Valente3.   

Abstract

INTRODUCTION: The International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification of lupus nephritis (LN) divides class IV into segmental and global (IV-S and IV-G) based on evidence suggesting different renal outcomes. However, subsequent studies have shown conflicting results.
OBJECTIVE: This study was performed to compare long-term renal outcomes between the IV-S and IV-G classes.
METHODS: This is a retrospective cohort study of adult patients with biopsy-proven class IV LN using the ISN/RPS classification. The primary end point was end-stage renal disease (ESRD).
RESULTS: Among the 89 patients, rapidly progressive glomerulonephritis was twice as frequent in the IV-G group (60 vs. 29%; p = 0.005) than that in the IV-S group. Moreover, the IV-G group had a higher rate of biopsy with cellular and fibrocellular crescents (70.9 vs. 47.1%, p = 0.024) and more crescentic glomerulonephritis (34.5 vs. 5.8%, p = 0.007) than the IV-S group. After a mean follow-up of 57 months, the IV-G group had a greater risk of ESRD (RR 3.9; 95% CI 1.2-12.2, p = 0.006) than the IV-S group. Multivariate analysis indicated that class IV-G was an independent predictor of ESRD.
CONCLUSIONS: Patients with class IV-G have a higher risk of ESRD than patients with class IV-S.
© 2020 S. Karger AG, Basel.

Entities:  

Keywords:  Classification; Kidney biopsy; Lupus nephritis; Outcomes

Mesh:

Substances:

Year:  2020        PMID: 31910408     DOI: 10.1159/000505404

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  1 in total

1.  Prognostic value of modified National Institute of Health activity and chronicity scoring in determining complete renal response in newly diagnosed lupus nephritis: a retrospective single centre study.

Authors:  Shivendra Singh; H C Sreenidhi
Journal:  Int Urol Nephrol       Date:  2022-01-22       Impact factor: 2.266

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.